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Catecholamine receptor binding in rat kidney: Effect of aging. Binding
to several receptors was compared in kidneys from 3- and 24-month-old
rats. In crude membrane preparations of aged rat kidneys, the number
of f32-adrenergic receptors was significantly reduced but the number of
total /3-adrenoceptors was unchanged. The high-affinity a-adrenocep-
tor component was significantly reduced in old rats, whereas the low-
affinity component was unchanged. The number of a2-adrenoceptors
showed a non-significant decrease. 3H-spiperone binding sites were
similar in young and old rats. For each receptor binding the KD values
were the same in young and old animals. The D1 dopaniLine receptor was
significantly reduced in old rats. In our experiments, age-related changes
of specific binding sites in the kidney were selective for some receptors
studied and did not seem to be due to general aging-induced membrane
modifications. Moreover, the renal and central receptors were sensitive
to aging differently in the same animal model.
Catecholamine receptors in the kidney modulate hemody-
namics [1] and electrolyte balance [1, 2]. Actually dopamine
receptors can regulate renal vascular tone and sodium excretion
[3, 4]. Alpha-adrenergic receptors have been found to mediate
renal vasoconstriction and blood flow redistribution from cor-
tical to medullary areas, and their activation induces a decrease
in urinary sodium excretion and a rise in renin secretion rate [51.
Finally, /3-receptors located on the juxtaglomerular cells in the
kidney mediate renin release [5, 6]. So far, a variety of
experimental models have been used to study catecholamine
receptors [1, 6—141 and different experimental approaches have
been employed to characterize them. At present, no uniform
information is available within a given animal species to evalu-
ate the influence of pathophysiological changes on receptor
number and affinity for specific ligands.
In the last few years the influence of aging on renal hemody-
namics and electrolyte excretion has been extensively studied
[151. The results of these investigations have showed that aging
of the kidney of experimental animals and humans is associated
with dramatic renal functional changes, mainly characterized
by a reduction in glomerular filtration rate, a decline in renal
blood flow and a progressive proteinuria. The cause of such
profound changes in renal functional parameters which develop
with age are not completely understood. It has been suggested
that elevated glomerular capillary pressures and flows contrib-
ute to the development of glomerular sclerotic lesion leading to
progressive renal insufficiency.
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With the present study we wanted to assess the distribution
of catecholamine receptors in the kidney and their affinity for
specific binding in rats at 3 and 24 months of age. Our results
can be relevant to the problem of age-associated changes in
renal hemodynamics.
Methods
Adult (3 months) and aged (24 months) male Sprague-Dawley
CD-COBS rats (Charles River, Calco, Italy) maintained in
standard laboratory conditions were used. The animals were
killed by decapitation and kidneys were immediately removed
and frozen at —80°C until binding experiments. The kidneys
were thawed, minced and homogenized in 50 volumes of
ice-cold washing buffer (as required for the different binding
assays except for DA receptors assays when 100 volumes were
used) using an Ultra-Turrax TP-1810 (2 >< 30 sec; Janke &
Kunkel GMBH & Co KG, Staufen, FRG). To obtain crude
membrane preparation, the homogenate was centrifuged at
50,000 x g for 10 minutes, the supernatant was discarded, the
pellet resuspended, incubated at 37°C for 10 minutes and
centrifuged at 50,000 x g for 10 minutes. The pellet was then
resuspended and filtered through four layers of sterile gauze to
remove large particulate matter, and centrifuged again. The last
pellet was resuspended just before the binding assay in 20
volumes of ice-cold incubation buffer.
3H-spiperone binding
Washing buffer was 50 mrvi Tris-HC1, pH 7.4, containing 3
mM CaCl. Incubation buffer was 50 mrvi Tris-HCI, pH 7.1,
containing 10 .tM pargyline, 5.7 mrvi ascorbic acid, 120 mrvt
NaCl, 2 mrvi CaC12, 5 mtvt KC1 and 1 mrvi MgCI2. For 3H-
spiperone binding, samples of I ml final volume containing 10
mg of tissue and 10 nrvi 3H-spiperone (S.A. 23.4 Ci/mmol, New
England Nuclear, Boston, Massachusetts, USA) were incu-
bated for 15 minutes at 37°C in the presence of unlabelled
spiperone Ito 1000 M. Non-specific binding was determined in
the presence of 10 tM (+)-butaclamol and represented 40% of
total binding.
3H-serotonin binding
Washing buffer was 50 mrvi Tris-HCI, pH 7.4. Incubation
buffer consisted of 50 mvt Tris-HCI, pH 7.7, containing 10 /.LM
pargyline; 5.7 mrs'i ascorbic acid; and 4 mrvi CaCl2. For 3H-
serotonin binding, samples of 1 ml final volume containing 10
mg of tissue and 4 nivt 3H-serotonin (S.A. 14.9 Ci/mmol,
Amersham International plc, Buckinghamshire, UK) were in-
cubated for 15 minutes at 37°C in the presence of unlabelled
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serotonin 0.5 to 5.000 nM or unlabelled spiperone 0.5 to 5000
flM.
3H-Ketanserin binding
Washing and incubation buffer was 50 mM Tris-HCI, pH 7.4.
For 3H-Ketanserin binding, samples of I ml final volume
containing 10 mg of tissue and 1 nM 3H-Ketanserin (S.A. 95
Ci/mmol, New England Nuclear) were incubated for 15 minutes
at 37°C in the presence of unlabelled serotonin 0.5 to 5,000 nM
or unlabelled spiperone 0.5 to 5,000 nM.
3H-SCH 23390 binding
Washing buffer was 50 mrt Tris-HCI, pH 7.4. Incubation
buffer was 50 mi Tris-HCI, pH 7.9, containing 1 mi EDTA and
4 mM MgSO. For 3H-SCH 23390 binding, samples of 1 ml final
volume containing 10 mg tissue and 2.5 nM 3H-SCH 23390 (S.A.
85 Ci/mmol, Amersham, mt. plc) were incubated for 30 minutes
at 25°C in the presence of unlabelled SCH 23390 0.1 to 100,000
n. Non-specific binding was determined in the presence of 100
/LM cis-fiupentixol and was about 80 to 85% of total binding.
3H-prazosin binding
Washing and incubation buffer was 50 mrvi Tris-HCI, pH 7.4.
For 3H-prazosin binding, samples of 1 ml final volume contain-
ing 10 mg of tissue and 0.01 to 6 nM 3H-prazosin (S.A. 80.9
Ci/mmol, New England Nuclear) were incubated for 30 minutes
at 25°C, Non-specific binding was determined in the presence of
100 LM phentolamine, and represented 40 to 45% of total
binding.
3H-yohimbine binding
Washing and incubation buffer was 50 m'vi Tris-HCI, pH 7.4.
For 3H-yohimbine binding, samples of 1 ml final volume con-
taining 10 mg of tissue and 5 nM 3H-yohimbine (S.A. 90
Ci/mmol, Amersham International plc) were incubated for 30
minutes at 25°C in the presence of unlabelled yohimbine 1 to
100,000 n. Non-specific binding was determined in the pres-
ence of 100 ILM phentolamine and was about 70% of total
binding.
3H-dihydroalpreno/ol (3H-DHA) binding
Washing and incubation buffer was 50 m Tris-HCI, pH 7.4.
For 3F1-DHA binding, samples of 1 ml final volume containing
10mg of tissue and 3}{-DHA (S.A. 58 Ci/mmol, Amersham; 0.35
to 6.7 n for saturation studies, 1 nM for inhibition studies)
were incubated for 25 minutes at 25°C in the presence of
different concentrations of l-phenyl-3(2-(3- (2-cyanophenoxy)
-2-hydroxypropyl)-aminoethyl) - hydantoin HCI (P0160) or zin-
terol. Non-specific binding was determined in the presence of 1
M (+1—)- propranolol, and corresponded to 60 to 70% of total
binding.
For all binding assays incubation was stopped by the addition
of ice-cold incubation buffer followed by rapid filtration under
vacuum through Whatman GFIB glass fiber filters, and three
washes with incubation buffer. Filters were counted in 8 ml of
Filter-Count scintillator (Packard Instrument Co. Inc., Down-
ers Grove, Illinois, USA) in a Beckman LS 7500 scintillation
counter (Beckman, Irvine, California, USA) at 50% efficiency.
Calculations
Binding parameters for 3H-spiperone, 3H-SCH 23390 and
3H-yohimbine were obtained using increasing concentrations of
unlabelled ligand; data were analyzed by non-linear fitting
according to the function:
[3F1-ligand]
[Inhib]\[3H-ligand] + K0 + (1 + Ki )
+ non-specific bound
by using the NL FIT program [16] running on the HP8S desk
computer. Binding parameters for other ligands were calculated
by non-linear fitting analysis of data from saturation experi-
ments using six to seven different concentrations of 3H-ligand,
each assayed in duplicate or triplicate, using the program
"Recept" running on an HP85 desk computer [171. For inhibi-
tion experiments binding parameters were calculated by non-
linear fitting analysis of data using 9 to 10 different concentra-
tions of inhibitor, each assayed in duplicate or triplicate, using
the "Recept" program [17].
Proteins were determined by the method of Peterson [18]
using bovine serum albumin as standard.
Drugs
The following were used: bovine serum albumin (Merck,
Darmstadt, FRG); spiperone and haloperidol (Janssen, Beerse,
Belgium); (+)-butaclamol and (—)-butaclamol (Research Bio-
chemical Inc., Wayland, Massachusetts, USA); phentolamine
(Ciba-Geigy, BasIc, Switzerland); P0160 (Pierrel, Milan, Italy);
zinterol (Mead Johnson and Company, Evansville, Indiana,
USA) and (+/—)-propranolol (ICI, Cheshire, UK). Serotonin
creatinine sulphate (Fluka AG, Buchs, CH), cis(Z)-flupentixol
(H Lundbeck & Co., Copenhagen, Denmark) and SCH 23390
(Schering Corp., Bloomfield, NJ, USA) were used.
Results
Kidney weight was significantly (P < 0.001) greater in old rats
(2.20 0.20 g for old and 1.49 0.15 g for young) and protein
concentration was significantly lower (P < 0.05) in aged animals
(31.96 5.56 mg/g tissue in old and 36.91 4.87 mg/g tissue in
young).
Kinetic parameters of 3H-spiperone binding, which is a
marker for D2 dopamine receptors, were similar in young and
old rats and indicated a very high density of binding sites (1200
pmol/mg protein) with low-affinity (Table 1). Similar results
were obtained when membrane preparations were carried out in
Tris HCI 50 mM, pH 7.4, without the addition of ions (Bmax
1706 228 pmol/mg protein, K0 19.82 2.94 >< l0 M).
Inhibition experiments with (+)-butaclamol gave an 1C50 of 8.6
14.1 x l0— M for young and 1.33 0.93 x lO M for old
animals. Using (—)-butaclamol we obtained an 1C50 of 1.63
0.29 x iO M for young and 4.11 2.8 x i0 M for old
animals, not significantly different from the values obtained
with the (+) form.
To test whether the renal receptor population bound by
3H-spiperone presented a serotoninergic component we mea-
sured 3H-serotonin and 3H-Ketanserin binding in the presence
Bound = Bmax
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of increasing concentrations of unlabelled serotonin and
spiperone. No specific binding was detected.
3H-SCH 23390 binding
The maximum number of D1 receptors (Bmax) was signifi-
cantly decreased in aged animals (1,631 94 and 816 54
fmol/mg protein in young and in old, respectively, P < 0.001;
Table 1). K0 was also slightly reduced in aged rats, due to
mathematical correlation between the two parameters.
3H-prazosin binding
Saturation experiments indicated two populations of a-1
adrenoceptors in kidney. The high-affinity component gave the
same KD in the two groups (0.03 n in young and 0.02 flM in
old) but a significantly lower number of receptors in aged
animals, with a Bmax of 23 4 fmol/mg protein in young and 11
2.9 fmol/mg protein in old (P <0.05; Table 1). No changes in
relation to aging were found in the low-affinity component.
3H-yohimbine binding
A non-significant decrease in a-2 adrenoceptor number was
found in aged rats (Bmax 70.8 29.2 fmol/mg protein in young
and 45.4 26.1 fmol/mg protein in old) and no changes in
affinity (Table I).
3H-dihydroalprenolol (3H-DHA) binding
Inhibition curves of I nM 3H-DHA binding (a marker for total
/3-adrenoceptors), obtained with the /3-i selective antagonist
P0160 (Fig. I) and /3-2 selective agonist zinterol (Fig. 1) are
reported. Competition curves for both compounds were best
fitted by a two-site model showing the presence of two
adrenoceptor populations with different affinities for the selec-
tive agents. The proportion of beta population that binds P0 160
at high-affinity represents the /3-i receptors, and P0160 low-
affinity binding represents the 13-2 receptors [19, 20]. Zinterol
binds with high-affinity /3-2 and with low-affinity /3-i receptor
subtypes [21].
' /
—10 —8.6 —7—5.4—3.8
Log [MI Log IM]
Fig. 1. 3H-DHA binding inhibition of P0160 and zinterol. Inhibition
curves of 3H-DHA (1 nM) by P0 160 (top) and zinterol (bottom) were
analyzed by non-linear fitting of experimental data, according to a
two-site model. For each inhibition curve the graphs report the final
fitting of experimental points and the calculated functions for high- and
low-affinity sites (Methods). Shown are inhibition curves of one animal,
representative of its group. Each point is mean value of 3 determina-
tions, varying less than 10%. y axis % inhibition of total 3H-DHA
binding; x axis = logarithm of drugs molar concentrations. Symbols are:
(A) unbroken line, young; (•) broken line, old.
Table 2 shows the percentage inhibition of specific renal
3H-DHA binding in young and old rats by zinterol and P0 160. In
this experiment we found an almost equal density of /3-i and 13-2
adrenergic receptors in young animals and a lower proportion of
13-2 subtype in old animals, with either P0 160 (low-affinity) or
zinterol (high-affinity).
Saturation curves using (+/—)-propranolol to define non-
specific binding showed that the total number of beta receptors
(/3-i + /3-2) was not changed by aging (Table 1). Using P0160 1
Table 1. Kinetic characteristics of different receptors in kidney of young and old rats
Receptor subtype 3H-Ligand Binding parameter
Age months
3 24
Dopamine
D1 3HSCH23390 BmafmolImg protein
K0 (nre)
1631.00 94.00
192.68 17.85
816.00 54.OOa
103.93 592b
D2 3H-spiperone Bmax pmol/mg protein
K0 /.LM
1200.00 140.00
22.40 3.20
1190.00 238.00
22.00 7.60
Adrenoceptors:
alpha-I 3H-prazosin
high-affinity
low-affinity
BfmolImg protein
K0 flM
Bmaxfmo//mg protein
K0 nM
23.00 4.00
0.03 0.04
850.00 332.00
28.70 14.30
11.00 2.90t
0.02 0.01
913.00 308.00
28.50 12.00
alpha-2 3H-yohimbine B,,axfmol/mg proteinK0 n
70.80 29.20
15.20 4.50
45.40 26.10
12.80 17.30
beta-I + beta-2 3H-dihydroalprenolol Bmaxfmollmg protein
KD nM
36.10 0.41
1.20 0.20
34.40 4.10
1.10 1.19
beta-I — Br,,axfmol/mg protein 15.70 0.60 21.50 2.60
beta-2 BaxfmolImg protein 20.50 0.20 12.90
Kinetic characteristics of the different ligands were calculated by non-linear fitting of binding data.
Results are means SD of 3 to 4 animals per group. B,ax values for total /3-adrenoceptors were obtained in presence of I M (+/—)-propranolol;
for /31 determination I M P0160 was used; /32 adrenoceptor numbers were calculated as the difference between the two values.
a P < 0.001, Student's t-testb P < 0.05, Student's t-test
C0
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Table 2. Inhibition of specific renal 3H-DHA binding in young and old rats by P0160 (beta I) and zinterol (beta 2)
High-affinity Low-affinity
%RT
IC50
flM %RT
IC50pi
P0160 young
P0160 old
Zinterol young
Zinterol old
52.00 15.00
64.00 14.00
48.00 25.00
24.00 20.40
17.50 17.30
27.60 19.10
103.00 120.00
26.90 59.00
48.00 20.00
36.00 17.00
52.00 22.60
76.00 18.30
4.60 8.30
12.20 26.00
5.70 8.90
3.80 3.60
3H-DHA was used at mM final concentration.
P0 160 and zinterol was used at concentrations of 0.1 to 100,000 nM
Data were calculated as means SD from the inhibition curves (of one animal) presented in Fig. 1, by two-site model fitting of the experimental
points.
Abbreviations are: % RT, percentage of total receptors; and IC50, drug concentration giving half maximal inhibition of specific binding.
M (concentration that completely blocks 13-i receptors; Fig. 1)
to define non-specific binding, we obtained saturation curves of
13-i receptors [20]. The amount of /3-2 subtype was obtained as
the difference between the two curves (Table 1). These data are
in agreement with those obtained in inhibition experiments and
showed a lower number of /3-2 receptors in aged rats (Table 1)
with an insignificant increase in the /3-i subtype.
Discussion
Our present results identify catecholamine receptors in the
rat kidney and characterize their binding parameters. In agree-
ment with previous studies we have documented the presence
of dopamine receptors, a-adrenergic receptors and /3-adrener-
gic receptors in whole kidney crude membrane preparations.
As far as dopamine receptors we have identified the presence
of D1 subtype, while we were not able to characterize high-
affinity and stereospecific D2 subtype in our preparation, but on
3H-spiperone binding sites. The identification of D1 receptors
has been possible by virtue of a specific radioligand, 3H-SCH
23390 [22] which has become available only recently and has
never been used to identify D1 receptor subtypes in the kidney
by binding studies, The results indicate a high-affinity binding to
D1 receptors. The direct documentation of the existence of D1
receptor in kidney homogenates supports previous work [23] in
which the vasodilatory and natriuretic response was studied in
dogs with and without pharmacological blockade of D1 receptor
with infusion of the specific D1 receptor antagonist SCH 23390.
Moreover our results are also consistent with the previous data
ofFelderet at [7] who documented the presence of D1 dopamine
receptors associated with adenylate cyclase in cortical tubules.
As to the 3H-spiperone binding sites, our results indicate a low-
affinity high-density binding, which in our hands using (+) and
(—) butaclamol was not stereoselective. Our studies are in
contrast with previous studies which identified high-affinity high
density, stereospecific D2 receptor in the kidney labelled by
3H-haloperidol or 3H-spiperone [7, 24]. These contradictory
results can be explained by the use of different experimental
conditions, like the strain of rats, the use of whole kidney and
the procedure used for membrane preparations and binding
measurements. Moreover, since spiperone can also bind sero-
toninergic receptors of SHT2 subtypes [25], we wondered
whether the differences in affinity and density found in the
present study in respect to previously published studies [7, 24]
were influenced by the presence of serotoninergic receptors.
Failure of both 3H serotonin and 3H Ketanserine, specific
ligands for serotoninergic receptors, to bind to kidney mem-
brane preparation in our experimental conditions would rule out
this possibility.
Alpha-adrenergic receptors have been studied using 3H-
prazosin and 3H-yohimbine. The results indicate the presence
of both a-I and a-2 receptor subtypes. Alpha-I receptors were
resolved into two components, one with low and one with high
affinity. As far as the receptor density the low-affinity compo-
nent prevailed, the number of receptor being about 40 times
more than the high-affinity component. These results are in
agreement with those of McPherson and coworkers [9] who
found that 3H-prazosin binds to rat renal cortex with two
binding sites, a low and a high-affinity one, the low-affinity
having the higher density. Alpha-2 receptor appears to consist
of a single class of high-affinity binding sites. The affinity and
density of renal a-2 receptor binding we found in the present
study were consistent with previously published work [10, 111.
Beta-adrenoceptors have been identified by 3H-dihydroal-
prenolol binding. The results showed a high-affinity, low den-
sity binding. Since 3H-dihydroalprenolol binds to both f3- and
13-2 receptor subtypes we have resolved the two components
using a selective /3-I antagonist P0160 [19, 20] and a selective
/3-2 agonist zinterol. It has been documented that rat kidney
membrane preparations possess both receptor subtypes with a
comparable density. These data are in agreement with those of
Healy, Munzel and Insel [13] who using autoradiographic
techniques found that both receptor subtypes are present in the
rat kidney with an approximately equal relative percentage
distribution.
When the results obtained in young rats were compared to
those of old rats a selective reduction in D1, high-affinity a-1 and
13-2 was documented whereas 3H-spiperone binding sites low-
affinity a-1, and /3-i were not changed by the process of aging. A
possible explanation for the changes in catecholamine receptor
density associated with aging rests on the observation that
plasma catecholamine concentrations are higher in aged than in
young rats [26]. Actually high plasma concentrations of epi-
nephrine has been found to down-regulate catecholamine re-
ceptors [27, 281. That this can be the case is consistent with the
observation that endogenous catecholamines can selectively
"down-regulate" a-1, but not a-2 adrenergic receptor in the
renal cortex [29]. An alternative explanation for the selective
reduction in D1, high-affinity a-1 and /3-2 in old versus young rats
could be the progressive reduction of parenchimal renal mass
which occurs as a consequence of aging in the rat. Whether this
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could account for the selective reduction in some but not in all
the catecholamine receptors cannot be established on the basis
of the results of the experiments presented here. Changes in
renal catecholamine receptors associated with aging in the rat
could not have been predicted from the known changes ob-
served under similar experimental condition in the rat brain.
Actually, in the brain aging is associated with a selective
decrease in the density of D2 receptors in the striatum [30] and
of total /3-adrenoceptors [311. This would imply that catechol-
amine receptors in different tissues are differently affected by
aging process, thus showing tissue-specific adaptive responses.
At the present stage of the knowledge about the functional
significance of catecholamine receptors in the kidney, it is
difficult to define the pathophysiological meaning of the ob-
served changes in relation to age. Whether the reduction in a-
adrenoceptors which have been shown to mediate adrenergic-
induced vasoconstriction [1] accounts for the age-related max-
imal vasodilation of residual glomeruli is a possibility which
merits investigation.
In conclusion, our findings identify and characterize cate-
cholamine receptors in the rat kidney and show that aging is
associated with a lowering of D1 subtypes, a-sand 13-2 thus
creating an imbalance in the relative density of the various
catecholamine receptors. The possibility that the disproportion
between tise various receptor subtypes alters renal hemody-
namics, thus accounting for adaptive changes associated with
aging kidney, is worth investigating.
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